HSBC Maintains Buy on Repligen, Lowers Price Target to $150

Repligen Corporation

Repligen Corporation

RGEN

0.00

HSBC analyst Sidharth Sahoo maintains Repligen (NASDAQ: RGEN) with a Buy and lowers the price target from $170 to $150.